BACKGROUND: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. METHODS: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. RESULTS: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. CONCLUSIONS: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.
BACKGROUND: The clinical significance and efficacy of treating patients who have immunoglobulin (Ig) G subclass deficiency and/or antibody deficiency with Ig-replacement therapy has been debated. There are no clear guidelines to recommend intravenous gammaglobulin (IgIV) in these patients as there are few published studies documenting its efficacy. METHODS: We studied in an open-label protocol 10 adult patients with recurrent respiratory infections and IgG subclass and/or antibody deficiency. All patients received monthly IgIV for 12 months and then were observed for 3 months without IgIV infusions. We studied quality of life, incidence of infections, need for antibiotics, frequency of hospitalizations due to infections, IgG subclass and antibody (tetanus and pneumococcal) levels. Innate immunity was evaluated by studying the status of Toll-like receptors and polymorphisms, mannan-binding lectin levels and genotypes. Correction of the immune defects during IgIV therapy was evaluated. RESULTS: Monthly IgIV significantly improved quality of life, decreased the number of infections and the need for antibiotics, and improved IgG subclass and antibody serum levels. No consistent finding of innate immunity could be detected. CONCLUSIONS: IgIV could be beneficial in patients with IgG subclass or antibody deficiency.
Authors: Asad Jehangir; Kyle Bennett; Shoaib Bilal Fareedy; Andrew Rettew; Bilal Shaikh; Anam Qureshi; Qasim Jehangir; Richard Alweis Journal: Case Rep Gastrointest Med Date: 2015-04-05
Authors: Joo Hee Kim; Sunghoon Park; Yong Il Hwang; Seung Hun Jang; Ki Suck Jung; Yun Su Sim; Cheol Hong Kim; Changhwan Kim; Dong Gyu Kim Journal: J Korean Med Sci Date: 2016-10 Impact factor: 2.153
Authors: Diana A van Kessel; Thijs W Hoffman; Heleen van Velzen-Blad; Pieter Zanen; Jan C Grutters; Ger T Rijkers Journal: EBioMedicine Date: 2017-03-21 Impact factor: 8.143
Authors: Joo Hee Kim; Young Min Ye; Ga Young Ban; Yoo Seob Shin; Hyun Young Lee; Young Hee Nam; Soo Keol Lee; You Sook Cho; Seung Hun Jang; Ki Suck Jung; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2017-11 Impact factor: 5.764